{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T19:06:20Z","timestamp":1773342380938,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007174","name":"Array BioPharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007174","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This phase I\/II trial evaluated the combination of the kinesin spindle protein inhibitor filanesib with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM) patients. Forty\u2010seven RRMM patients with a median of three prior lines (2\u20138) and 94% refractory to lenalidomide were included: 14 in phase I and 33 in phase II. The recommended dose was 1\u00b725 mg\/m<jats:sup>2<\/jats:sup> of filanesib on days 1, 2, 15, 16, with pomalidomide 4 mg on days 1\u201321 and dexamethasone 40 mg weekly. The defined threshold for success was achieved, with 18 out of 31 patients obtaining at least minor response (MR) in the phase II. In the global population, 51% of patients achieved at least partial response (PR) and 60% \u2265MR, resulting in a median progression\u2010free survival (mPFS) of seven months and overall survival (OS) of 19 months. The main toxicity was haematological. Importantly, patients with low serum levels of alpha 1\u2010acid glycoprotein (AAG) at baseline (&lt;800 mg\/l) had a superior response (overall response rate of 62% vs. 17%; <jats:italic>P<\/jats:italic> = 0\u00b704), which also translated into a longer mPFS (9 vs. 2 months; <jats:italic>P<\/jats:italic> = 0\u00b7014). In summary, filanesib with pomalidomide and dexamethasone is active in RRMM although with significant haematological toxicity. Most importantly, high levels of AAG can identify patients unlikely to respond to this strategy.<\/jats:p><jats:p><jats:bold>Trial registration:<\/jats:bold> <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link> identifier: NCT02384083.<\/jats:p>","DOI":"10.1111\/bjh.16788","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T13:06:47Z","timestamp":1591362407000},"page":"522-530","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1\u2010acid glycoprotein (AAG) levels. Phase Ib\/II Pomdefil clinical trial conducted by the Spanish MM group"],"prefix":"10.1111","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5765-0085","authenticated-orcid":false,"given":"Enrique M.","family":"Ocio","sequence":"first","affiliation":[{"name":"Hospital Universitario Marqu\u00e9s de Valdecilla (IDIVAL) Universidad de Cantabria Santander Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Motll\u00f3","sequence":"additional","affiliation":[{"name":"ICO Badalona Hospital Germans Trias i Pujol Badalona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Rodr\u00edguez\u2010Otero","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universidad de Navarra, CIMA IDISNA, CIBERONC Pamplona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5904-0902","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Mart\u00ednez\u2010L\u00f3pez","sequence":"additional","affiliation":[{"name":"Hospital 12 de Octubre Universidad Complutense CNIO Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00aa Jos\u00e9","family":"Cejalvo","sequence":"additional","affiliation":[{"name":"Hospital Universitario Doctor Peset. Departamento de Medicina Interna y Odontolog\u00eda Universidad Cat\u00f3lica de Valencia Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Mart\u00edn\u2010S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen del Roc\u00edo Sevilla Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[{"name":"Hospital Clinic de Barcelona Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00aa Dolores","family":"Garc\u00eda\u2010Malo","sequence":"additional","affiliation":[{"name":"Hospital Morales Meseguer IMIB\u2010Arrixaca Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00aa Victoria","family":"Dourdil","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Lozano Blesa IIS Arag\u00f3n Zaragoza Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ar\u00e1nzazu","family":"Garc\u00eda\u2010Mateo","sequence":"additional","affiliation":[{"name":"Hospital General de Segovia Segovia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"de Arriba","sequence":"additional","affiliation":[{"name":"Hospital Morales Meseguer IMIB\u2010Arrixaca Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Garc\u00eda\u2010Sanz","sequence":"additional","affiliation":[{"name":"Complejo Asistencial Universitario de Salamanca (IBSAL) y Centro de Investigaci\u00f3n del C\u00e1ncer (IBMCC\u2010CSIC) Universidad de Salamanca Salamanca Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-768X","authenticated-orcid":false,"given":"Javier","family":"de la Rubia","sequence":"additional","affiliation":[{"name":"Hospital Universitario Doctor Peset. Departamento de Medicina Interna y Odontolog\u00eda Universidad Cat\u00f3lica de Valencia Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"ICO Badalona Hospital Germans Trias i Pujol Badalona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan\u2010Jos\u00e9","family":"Lahuerta","sequence":"additional","affiliation":[{"name":"Hospital 12 de Octubre Universidad Complutense CNIO Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jes\u00fas F.","family":"San\u2010Miguel","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universidad de Navarra, CIMA IDISNA, CIBERONC Pamplona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda\u2010Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Complejo Asistencial Universitario de Salamanca (IBSAL) y Centro de Investigaci\u00f3n del C\u00e1ncer (IBMCC\u2010CSIC) Universidad de Salamanca Salamanca Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90142-6"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/359540a0"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e05-02-0167"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0033"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30892"},{"key":"e_1_2_7_12_1","first-page":"337","article-title":"Pharmacokinetic and pharmacodynamic consequences of altered binding of drugs to alpha 1\u2010acid glycoprotein","volume":"300","author":"Belpaire FM","year":"1989","journal-title":"Prog Clin Biol Res"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2257.2003.00492.x"},{"key":"e_1_2_7_14_1","first-page":"1868","article-title":"Identification of Alpha 1\u2010Acid Glycoprotein (AAG) As a Potential Patient Selection Biomarker for Improved Clinical Activity of the Novel KSP Inhibitor ARRY\u2010520 in Relapsed and Refractory Multiple Myeloma (MM)","volume":"120","author":"Tunquist B","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.168666"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.3167.3167"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-682518"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-643320"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30174"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.16788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.16788","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T13:04:13Z","timestamp":1692968653000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1111\/bjh.16788"],"URL":"https:\/\/doi.org\/10.1111\/bjh.16788","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"assertion":[{"value":"2020-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}